11C-Choline PET/CT Predicts Prostate Cancer–Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy
Rattachement africain : ch, it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
UNLABELLED: Several studies have shown that (11)C-choline PET/CT may be useful for restaging prostate cancer (PCa) patients with biochemical failure after radical prostatectomy. However, validation of (11)C-choline PET/CT findings scarcely relied on histologic findings, and prognostic implications of (11)C-choline PET/CT are currently unknown. The aim of this study was to assess whether (11)C-choline PET/CT predicts survival in PCa patients. METHODS: This retrospective study included 195 PCa patients treated with radical prostatectomy who underwent (11)C-choline PET/CT from December 1, 2004, to July 31, 2007, due to biochemical failure (prostate-specific antigen > 0.2 mg/mL) during androgen-deprivation therapy. PCa-specific survival was computed as the interval from radical prostatectomy to PCa-specific death. RESULTS: The median interval after radical prostatectomy was 8.9 y (95% confidence interval [CI], 1.7-18.9 y). The median follow-up after (11)C-choline PET/CT was 4.5 y (95% CI, 0.4-8.5 y). (11)C-choline PET/CT results were positive in 57% of patients. The median PCa-specific survival was 16.4 y (95% CI, 14.0-18.8 y) in patients with negative (11)C-choline PET/CT results and 11.2 y (95% CI, 9.8-12.6 y) in patients with positive (11)C-choline PET/CT results (log-rank: χ(2) = 19.3, P < 0001). At multivariate analysis, statistical significance was obtained for (11)C-choline PET/CT (hazard ratio, 2.53; 95% CI, 1.41-4.53; P = 0.002), prostate-specific antigen (hazard ratio, 1.03; 95% CI, 1.00-1.05; P = 0.037), and Gleason score (>7: hazard ratio, 2.49; 95% CI, 1.25-4.95; P = 0.009). Patients with pathologic (11)C-choline uptake in the prostatic bed or in pelvic or retroperitoneal lymph nodes had longer PCa-specific survival (median, 12.1 y; 95% CI, 10.5-13.7 y) in comparison to patients with pathologic tracer uptake in the skeleton (median, 9.9 y; 95% CI, 6.8-13.1 y) (log-rank: χ(2) = 6.5, P = 0.010). Two internally validated nomograms predicted 10- and 15-y PCa-specific survival probability with an accuracy of 76% and 74%, respectively. In an ancillary analysis, we also showed that (11)C-choline PET/CT predicts PCa-specific survival after PET/CT, with similar statistical power. CONCLUSION: (11)C-choline PET/CT predicts PCa-specific survival in PCa patients treated with radical prostatectomy who develop biochemical failure during androgen-deprivation therapy. If independent or multicenter confirmation of these findings is obtained, (11)C-choline PET/CT might be more widely used in the follow-up of PCa patients for tailoring salvage therapy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- <sup>11</sup>C-Choline PET/CT Predicts Prostate Cancer–Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy
- Date Crossref
- 09/01/2014
- Éditeur
- Society of Nuclear Medicine
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Triemli Hospital pays non établi dans la noticeÉtablissement de santé
-
Stadtspital Waid pays non établi dans la noticeÉtablissement de santé
-
San Raffaele University of Rome pays non établi dans la noticeUniversité ou école supérieure
-
University of Milano-Bicocca Department of Health Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Swiss Tropical and Public Health Institute pays non établi dans la noticeStructure de recherche
-
Institute of Molecular Bioimaging and Physiology pays non établi dans la noticeStructure de recherche
-
Azienda Ospedaliera San Gerardo pays non établi dans la noticeÉtablissement de santé
-
National Research Council pays non établi dans la noticeOrganisation à but non lucratif
-
Department of Radiology pays non établi dans la noticeInstitution
-
San Raffaele Scientific Institute Department of Nuclear Medicine pays non établi dans la noticeStructure de recherche
-
San Gerardo Hospital Department of Nuclear Medicine pays non établi dans la noticeÉtablissement de santé
-
Institute for Molecular Bioimaging and Physiology pays non établi dans la noticeStructure de recherche
Triemli Hospital, Stadtspital Waid et San Raffaele University of Rome, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.